Michael Posternak, MD.
Psychiatrist in private practice, Boston, MA.
Dr. Posternak has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Not satisfied with its claim to improve cognitive features of depression, Trintellix has ventured into new therapeutic arenas. Sometimes with success, sometimes with failure, we review where this novel antidepressant stands in schizophrenia, anxiety, cognitive decline, ADHD, sexual dysfunction, and binge eating disorder.